Immunic Inc IMUX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Immunic to Participate in Investor Conferences in July
-
Immunic to Participate in Investor, Industry and Scientific Conferences in June
-
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
-
Immunic Names Erik Lundgren Chief Executive
-
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
-
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
-
Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
Immunic to Participate in Investor and Medical Conferences in May
Trading Information
- Previous Close Price
- $14.69
- Day Range
- $14.50–15.25
- 52-Week Range
- $5.06–15.84
- Bid/Ask
- $14.20 / $0.00
- Shares Outstanding
- 13.62M
- Market Cap
- $205.68M
- Volume/Avg
- 5 / 264,727
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 95
- Website
- https://www.imux.com
Valuation
|
Metric
|
IMUX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IMUX
|
|---|---|
Quick Ratio | 4.87 |
Current Ratio | 4.92 |
Interest Coverage | — |
Quick Ratio
IMUX
Profitability
|
Metric
|
IMUX
|
|---|---|
Return on Assets (Normalized) | −138.21% |
Return on Equity (Normalized) | −253.15% |
Return on Invested Capital (Normalized) | −252.41% |
Return on Assets
IMUX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|M#&b^!& | LOCK|M^bG | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|FrZw@< | LOCK|>@@V | $70B | |||
| argenx SE ADR
ARGX
| LOCK|dC$%vwn | LOCK|%G | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@lcnX? | LOCK|tQRx | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^d&L<vC | LOCK|^Mb | $37B | |||
| Moderna Inc
MRNA
| LOCK|t$!yg& | LOCK|m$ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#cs@fp> | LOCK|@!gKC | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|$!Jn<t | LOCK|kw# | $23B | |||
| Incyte Corp
INCY
| LOCK|!?Z%nq | LOCK|T%t | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|v&$m%WL | LOCK|<? | $16B |
United States